80%Confidence
0Views
FDASource
2026-04-04Date
Summary
Rising Pharma's Temozolomide stability failure suggests potential degradation issues in their oncology product line, which could impact treatment efficacy. This may trigger broader quality reviews of their manufacturing processes and affect market confidence.
Actionable: Review inventory of Temozolomide capsules and verify stability data with alternative suppliers.
AI Confidence: 80%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now